

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)  SHEET <input type="text" value="1"/> OF <input type="text" value="5"/>	<i>Complete if Known</i>	
	Application Number - 10/005,438	
	Filing Date - Dec. 3, 2001	
	First Named Inventor - Tse Wen Chang	
	Group Art Unit - 1842	
	Examiner Name - S. UNGAR	
Attorney Docket Number TNX95-2ABB		

U.S. PATENT DOCUMENTS					
Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number Code	Kind (if known)			
LC	✓ 4973478	B1	Gauldie, et al.	05/24/1989	
	✓ 5004805	B1	Hershenson, et al.	04/02/1991	
	✓ 5460811	B1	Goeddel, et al.	10/24/1995	
	✓ 5468609	B1	Revel, et al.	11/21/1995	
	✓ 5468608	B1	Revel, et al.	11/21/1995	
ff	5468607	B1	Revel, et al.	11/21/1995	

FOREIGN DOCUMENTS							
Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	Office	Number	Kind Code (If known)				
LC	EP	0083089	B1	Itoh, et al.	08/11/1987		
	EP	0084681	A2	Taniguchi, et al.	11/17/1992		
	EP	0467416	A1	Burnett, et al.	01/22/1992		
Be	WO	9118353	A1	Lerocha, et al.	10/31/1991		

Examiner Signature	<i>Byron Clark</i>	Date Considered	4/14/05
-----------------------	--------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031  
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<b>Complete if Known</b>	
	Application Number 10/005,438	
	Filing Date Dec. 3, 2001	
	First Named Inventor - Tse Wen Chang	
	Group Art Unit 1642	
	Examiner Name S. UNGAR	
SHEET <input type="text" value="2"/> OF <input type="text" value="5"/>	Attorney Docket Number TNX95-2ABB	

U.S. PATENT DOCUMENTS					
Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number Code	Kind (if known)			
bc	5015730	B1	Friesen, et al.	05/14/1991	
	4289658	B1	Friesen, et al.	08/15/1991	
	5428130	B1	Capon, et al.	08/27/1993	
bc	5346053	B1	Landolfi	08/20/1994	

FOREIGN DOCUMENTS						
Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Office	Number	Kind Code (if known)			

Examiner Signature	<i>Syan cheng</i>	Date Considered	4/14/05
-----------------------	-------------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET 3 OF 5**Complete If Known**

Application Number 10/005,438

Filing Date Dec. 3, 2001


First Named Inventor Tse Wen Chang

Group Art Unit 1642

Examiner Name S. UNGAR

Attorney Docket Number TNX95-2ABB

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	T <sub>2</sub>
gc		Huston, JS, et al., <i>Methods in Enzymology</i> , 203:46-88.	
		Landolin, N.F., <i>J. Immunol.</i> , 146:915-918 (1991), Chimeric IL-2/Ig Molecule.	
gc		Peterhans, A., et al., <i>Analytical Biochemistry</i> , 163(2) 470-75.	
		Baron, E. and Narula S., <i>Biotechnology</i> , 10:179-190, 1990, From cloning to a commercial realization: Human alpha interferon.	
		Bocsi, V., <i>Interferon</i> , 4:47-72, 1985, Distribution, catabolism and pharmacokinetics of interferons.	
		Bohostawec, O. et al., <i>J. Interferon Res.</i> , 6:207-213, 1986, Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I Interferons and mouse alpha-Interferon in Mice.	
		Bonetti, A. and Kim, S. <i>Cancer Chemother Pharmacol.</i> 33:258-281, 1993, Pharmacokinetics of an extended-release human interferon alpha-2b formulation.	
		Brown, K.D. <i>Genetic Engineering News</i> , 15:1-35, 1995, Novel emerging therapeutics target the hepatitis C virus.	
		Bruni, J.V., <i>Biotechnology</i> , 7:549, 1989, Interferon trials proliferate.	
		Cantell, K. et al., <i>Methods in Enzymology</i> , 78A:29-38, Academic Press, 1981.	
		Coligan, J.E. et al., <i>Current Protocols in Immunology</i> , pp 6.9.1-6.9.8, Current Protocols, 1991, Measurement of antiviral activity induced by Interferon $\alpha$ , $\beta$ , and $\gamma$ .	
		Daugherty, S.L. et al., <i>Nucleic Acids Res.</i> 19:2471-6, 1991, Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins.	
		Dianzani, E.J., <i>Interferon Res. (Special Issue)</i> 109-118, 1992, Interferon treatments: how to use an endogenous system as a therapeutic agent.	
Examiner Signature			Date Considered 4/14/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET 4 OF 5**Complete if Known**

Application Number 10/008,438

Filing Date Dec. 3, 2001


First Named Inventor Tse Wen Chang

Group Art Unit 1842

Examiner Name S. UNGAR

Attorney Docket Number TNX95-2ABB

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s).	T 1
<del>_____</del>	<del>_____</del>	<del>Evinger, M. and Pestka, S., <i>Methods in Enzymology</i>, 79:382-8, Assay of growth inhibition in lymphoblastoid cell cultures.</del>	
<del>_____</del>	<del>_____</del>	<del>Goeddel, D.V. et al., <i>Nature</i>, 290:20-28, 1981, The structure of eight distinct cloned human leukocyte interferon cDNAs</del>	
<del>_____</del>	<del>_____</del>	<del>Guterman, J., <i>Proc. Nat. Aca. Sci.</i> 91:1198-1205; 1994, Cytokine therapeutics: lessons from interferon <math>\alpha</math>.</del>	
<del>_____</del>	<del>_____</del>	<del>Johns, T.G. et al., <i>Cancer Res.</i>, 50:4718-23, 1990, Pharmacokinetics, tissue distribution, and cell localization of [<math>^{35}</math>S] methionine-labeled recombinant human and murine <math>\alpha</math> interferons in mice.</del>	
<del>_____</del>	<del>_____</del>	<del>Kabat, E.A. et al., <i>Sequences of proteins of Immunological Interest</i>, pp 1582-88, NIH, 1991</del>	
<del>_____</del>	<del>_____</del>	<del>Kurschner, C. et al., <i>J. Immunol.</i> 149:4096-4100, 1992, IFN-<math>\gamma</math> receptor-Ig fusion proteins.</del>	
<del>_____</del>	<del>_____</del>	<del>Mordenti, J. et al., <i>Nature</i>, 337:525-31, 1989, Designing CD4 immunoadhesins for AIDS therapy.</del>	
<del>_____</del>	<del>_____</del>	<del>Quesada, J.R. et al., <i>J. Clin. Oncol.</i> 4:234-243, 1986, Clinical toxicity of interferons in cancer patients: a review</del>	
<del>_____</del>	<del>_____</del>	<del>Roche Labs, Referon A, Schering, Intron A, <i>Physicians' Desk Reference</i>, 47 edition, 1993, pp. 2006-2008, 2194-2201.</del>	
<del>_____</del>	<del>_____</del>	<del>Roitt, I., <i>Essential Immunology</i>, 7<sup>th</sup> edition, 1991, Blackwell Scientific Publications, pp. 45-51, Immunoglobulin classes and subclasses.</del>	
<del>_____</del>	<del>_____</del>	<del>Saiki, R.K. et al., <i>Science</i>, 239:487, 1988, Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.</del>	
<del>_____</del>	<del>_____</del>	<del>Sambrook, J. et al., <i>Molecular cloning</i>, 1989, Cold Spring Harbor Laboratory Press, pp. 16.28-16.29.</del>	
<del>_____</del>	<del>_____</del>	<del>Schein, C.H. and Nisbet, H.M., <i>Bio/technology</i>, 6:291-294, 1988, Formation of soluble recombinant proteins in <i>Escherichia coli</i> is favored by lower growth temperature.</del>	
Examiner Signature			Date Considered 4/14/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

5

OF

5

**Complete if Known**

Application Number 10/005,438

Filing Date Dec. 3, 2001

First Named Inventor Tse Wen Chang

Group Art Unit 1642

Examiner Name S. UNGAR

Attorney Docket Number TNX85-2ABB

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s).	72
<del>_____</del>		Scorer, C.A. <i>et al.</i> , <i>Gene</i> , 138:111-9, 1993, The intracellular production and secretion of HIV-1 envelope protein in the methylotrophic yeast <i>Pichia pastoris</i> .	
<del>_____</del>		Strander, H. <i>Adv. Cancer Res.</i> 46:1-265, 1986, Interferon treatment of human neoplasia.	
<del>_____</del>		Tabata, Y. <i>et al.</i> , <i>Cancer Res.</i> 51:5532-8, 1991, Effects of recombinant alpha-Interferon-gelatin conjugate on in vivo murine tumor cell growth.	
<del>_____</del>		Von Gabain, A. <i>et al.</i> , <i>Eur. J. Biochem.</i> 190:257-61, 1990, Three human interferon- $\alpha$ 2 subvariants disclose structural and functional differences.	
<del>_____</del>		Weissmann, C. and Weber, H. <i>Prog. Nuc. Acid Res. Mol. Biol.</i> 33:251-300, 1986, The interferon genes.	
<del>_____</del>		Wilkinson, D.L. and Harrison, R.G., <i>Bio/technology</i> , 9:443-448, 1991, Predicting the solubility of recombinant proteins in <i>Escherchia coli</i> .	
<del>_____</del>		Zoon, K.C. <i>Interferon</i> , 9:1-12, 1987, Human Interferons: structure and function.	
<del>_____</del>		Physicians' Desk Reference 2194-2201	
<del>_____</del>		Capon, D. <i>et al.</i> , <i>Nature</i> , 337:525-531, 1989, Designing CD4 Immunoadhesions for AIDS Therapy	
Examiner Signature	<i>Syuan Chue</i>		Date Considered 4/19/05

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.